Huaier granules with standard therapy for early triple-negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial looks at whether adding Huaier granules to usual after-surgery treatment can improve outcomes for people with high-risk early-stage triple-negative breast cancer. It focuses on whether the added supplement is safe and helpful after standard care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 70 years old
- Your breast cancer is confirmed as invasive ductal cancer and is triple-negative
- You have higher-risk features (for example, lymph node spread found after surgery, or cancer not fully gone after pre-treatment chemotherapy)
- There is no current local return of cancer and no spread to distant organs
- You start the study soon after your postoperative (after-surgery) treatment—either during it or within 60 days after finishing
- Your overall health tests are within limits (good kidney/liver function and blood counts), and your activity level is mild (ECOG 0–1)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests a treatment for people with triple-negative breast cancer that has come back or spread and has continued to progress despite earlier therapies. It may help by trying a new approach in patients who still have enough health to safely receive more treatment.
This trial tests whether adding an immunotherapy drug (HLX10) to chemotherapy before surgery, and then continuing it after surgery, helps people with triple-negative breast cancer more than chemotherapy alone. It is a type of breast cancer that does not respond to hormone treatments or HER2-targeted treatments.
This trial tests whether a combination of chemotherapy drugs (nab-paclitaxel and carboplatin) plus an immunotherapy drug (PD1 inhibitor) given before surgery can help treat early-stage triple-negative breast cancer. It aims to improve outcomes by using these treatments before the main surgery.
This trial tests whether Huaier granules, a traditional Chinese medicine, can help people with advanced breast cancer that has not spread to major organs like the liver or lungs. You may join if you've had no more than one prior treatment and your cancer is not curable with surgery or radiation.
This study tests whether a traditional Chinese herbal medicine called Huaier granules can help lower tumor marker levels in the blood of people who have been treated for breast cancer. Tumor markers are substances that can indicate whether cancer is present or active; lowering them may be a sign that the cancer is under control.
This trial tests whether Huaier Granule, a traditional Chinese medicine, can help reduce protein in the urine (proteinuria) in people with breast cancer who are undergoing or have had immunotherapy. The goal is to see if this treatment can protect your kidneys and improve your quality of life during cancer therapy.
Hear when a new Triple Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.